Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report. (27th September 2022)

• Record Type: Journal Article
• Authors: Li, Jennifer Chen; Siglin, Jonathan; Marshall, Michael S; Stemmer-Rachamimov, Anat; Bloom, Seth M; Blumenthal, Kimberly G
• Is Part Of: Open forum infectious diseases. Volume 9:Number 10(2022)
• Publication Date: 2022-09-27
• Subjects: COVID-19 -- myositis -- mRNA vaccine -- SARS-CoV-2; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac499
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.